LEAP THERAPEUTICS, INC.
6,571,428 Shares of Common Stock
and Warrants to Purchase up to 6,571,428 Shares of Common Stock
https://www.sec.gov/Archives/edgar/data/1509745/...a2237643z424b5.htm
|
LEAP THERAPEUTICS, INC.
6,571,428 Shares of Common Stock
and Warrants to Purchase up to 6,571,428 Shares of Common Stock
https://www.sec.gov/Archives/edgar/data/1509745/...a2237643z424b5.htm
https://www.sec.gov/Archives/edgar/data/1509745/...a18-19040_110q.htm
https://www.sec.gov/Archives/edgar/data/1509745/...a2237643z424b5.htm
Cash and cash equivalents zum Ende Q3 waren 23,249 Mio$
Vorrausschauend haben sie das cash zum Ende Q4 mit 16,3 Mio$ angegeben.
Verbrennen vorraussichtlich um die 7 Mio$ im Q.
Mit der KE sollten sie, gerechnet ab Q1, mit 28,7 Mio cash veranschlagt werden.
As of November 6, 2018 there were 14,703,159 shares of the registrant’s common stock,
Common stock to be outstanding immediately after this offering | 21,274,587 shares of common stock (or 22,260,301 shares of common stock if the underwriters exercise their option to purchase additional shares and/or warrants in full). |
Die KE mit 6,571,428 Shares of Common Stock and 6,571,428 Warrants
Bei der KE haben sie für jede Aktie mit Warrant 1,75$ bezahlt. Wobei jeder Warrant noch einen Ausübungspreis von $1.95 per share besitzt.#
Ausgehend von 22,26 Mio Aktien und einem Kurs von 1,47, ergibt eine MK von 32,7 Mio bei einem cash von rund 28 Mio$.
Die Pipeline: https://www.leaptx.com/our-pipeline
Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities
https://www.ariva.de/news/...s-closing-of-public-offering-and-7393589
https://www.ariva.de/news/...nt-at-the-society-of-gynecologic-7455424
the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer.
https://www.ariva.de/news/...esents-at-society-of-gynecologic-7470993
Poster https://docs.wixstatic.com/ugd/...03e4ba126f3464d9a0d078841bea21b.pdf
Leap believes that its current cash and the expected receipt of research and development tax incentives will be sufficient to fund its operating expenses into the second quarter of 2020.
As of March 26, 2019 there were 22,260,301 outstanding shares of the registrant's common stock
https://www.ariva.de/news/...inical-update-and-2018-financial-7501801
Über die max. Aktienanzahl die von Leap verkauft werden dürfen.
Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference
CAMBRIDGE, Mass., April 3, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the 2019 Needham & Company 18th Annual Healthcare Conference, being held in New York City on April 9-10, 2019.
https://investors.leaptx.com/news-releases/...ham-company-18th-annual
-2019 finanziert!
We expect that our cash and cash equivalents of $16.3 million at December 31, 2018, together with the net proceeds from the February 2019 Public Offering of $12.1 million and the receipt of $0.8 million of research and development tax incentive payments from the Commonwealth of Australia as a result of the 2018 research and development activities of our Australian subsidiary, HealthCare Pharmaceuticals Pty Ltd, will be sufficient to fund our operating expenses for at least the next 12 months from issuance of the financial statements included in this Annual Report on Form 10-K
DKN-01
Combination with KEYTRUDA®
•Enrollment complete: 52 PD-1/PD-L1 naïve patients
•Mature data Q3 2019•Clinical outcomes in GEJ/Gastric patients
•Enabling biomarkers --DKK1, PD-L1
Monotherapy and Combination with paclitaxel
•78 patients enrolled across 4 treatment arms
•Updated efficacy data Q3 2019
•Enabling biomarkers –activating Wntpathway mutations, DKK1
TRX518
Combination with KEYTRUDA®/OPDIVO
•12 patients enrolled in Keytruda expansion, 20 total expected in Q2 2019
•Efficacy data Q4 2019
https://docs.wixstatic.com/ugd/c343d0_8716992ddbf44ecbaf4474ebc3d8f46a.pdf
https://www.ariva.de/news/...onference-call-to-provide-dkn-01-7727054
Zahlen für Q3/19
investors.leaptx.com/news-releases/...-2019-financial-results
seekingalpha.com/news/...cs-bails-2-program-shares-43-percent
Lizenzvereinbarung für DKN-01 mit BeiGene
investors.leaptx.com/news-releases/...ce-exclusive-option-and
www.pharmaceutical-business-review.com/...reement-for-dkn-01/
Orphan Drug Designation für DKN-01
investors.leaptx.com/news-releases/...drug-designation-dkn-01
Offering im Anmarsch
investors.leaptx.com/news-releases/...ublic-offering-common-1
Zahlen für Q1/20
investors.leaptx.com/news-releases/...-2020-financial-results
Zahlen für Q4/20
investors.leaptx.com/news-releases/...rter-and-full-year-2020
Zahlen für Q1/21
investors.leaptx.com/news-releases/...-2021-financial-results
Zahlen für Q2/21
"We look forward to presenting initial data from the study in September, which we believe will show the important potential role DKN-01 can play for first-line gastric cancer patients, particularly those whose tumors express high levels of DKK1 where a great unmet medical need remains unaddressed."
investors.leaptx.com/news-releases/...-2021-financial-results
neue positive Daten in der DisTinGuish Studie von DKN-01 + Tislelizumab
investors.leaptx.com/news-releases/...sitive-data-distinguish
Offering im Anmarsch
investors.leaptx.com/news-releases/...ublic-offering-common-2
90 Mio. $ Offering (Stammaktien und "Pre-Funded Warrants")
investors.leaptx.com/news-releases/...illion-common-stock-and
BeiGene hält 13,2% an LPTX
Einigen sehen in LPTX schon den nächsten Übernahmekandidaten. Dem Kurs tun solche Nachrichten natürlich gut. LPTX notiert knapp unter seinem 52 WH. Sieht man momentan auch nicht so oft im Biotech-Bereich.
investors.leaptx.com/node/8571/html
Zahlen für Q3/21
investors.leaptx.com/news-releases/...-2021-financial-results
neue Daten von DKN-01 + tislelizumab
investors.leaptx.com/news-releases/...-data-distinguish-study
Zahlen für Q4/21
investors.leaptx.com/news-releases/...rter-and-full-year-2021
Der Deal mit BGNE ist zwar auf den ersten Blick positiv, andererseits sind chinesische Unternehmen ein rotes Tuch für die USA.
ASCO-Abstrakt
investors.leaptx.com/news-releases/...-investigator-sponsored
Zahlen für Q1/22
investors.leaptx.com/news-releases/...-2022-financial-results
Leap Therapeutics beginnt neue klinische Studien mit DKN-01
investors.leaptx.com/news-releases/...ion-new-dkn-01-clinical
Zahlen für Q2/22
- expected to provide financial runway to mid-2024
investors.leaptx.com/news-releases/...-2022-financial-results
Zahlen für Q3/22
investors.leaptx.com/news-releases/...-2022-financial-results
Leap übernimmt Flame Biosciences
investors.leaptx.com/news-releases/...uires-flame-biosciences
BeiGene lässt Option für DKN-01 ablaufen
"Mit den weltweiten Rechten an DKN-01 und einer Cashreichweite, die durch unsere jüngste Übernahme von Flame Biosciences bis Mitte 2025 erweitert wurde, werden wir versuchen, einen neuen strategischen Partner zu finden[...]"
investors.leaptx.com/news-releases/...ne-option-agreement-dkn
Details aus der Mergervereinbarung
"In the merger, Leap will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders. Upon approval by the stockholders of Leap, each share of the Series X non-voting convertible preferred stock will be automatically converted into 1,000 shares of common stock"
ir.humanigen.com/English/news/...nancial-Results/default.aspx
Zahlen für Q4/22
investors.leaptx.com/news-releases/...rter-and-full-year-2022
Zahlen für Q1/23
investors.leaptx.com/news-releases/...-2023-financial-results
1/10 RS
investors.leaptx.com/news-releases/...ces-reverse-stock-split
Zahlen für Q2/23
investors.leaptx.com/news-releases/...-2023-financial-results
Zahlen für Q3/23
- Leap continued to make great strides this quarter including advancing into the 130 patient, randomized controlled Part B of the DeFianCe study evaluating DKN-01 plus bevacizumab and chemotherapy in second-line colorectal cancer, after exceeding our 20% overall response rate threshold in Part A. We are excited by the progress made and plan on presenting new data from Part A at a medical conference in January 2024
investors.leaptx.com/news-releases/...-2023-financial-results
Seit meinem letzten Posting ist LPTX in der Spitze bis auf 5$ gestiegen (+233%). Mittlerweile wurden diese Kursstände wieder größtenteils abgegeben. Mit 71 Mio. $ Cash zum Jahresende und einem Verlust von 81 Mio. $ in 2023 stellt sich auch die Frage nach der Cashreichweite bzw. zukünftiger Finanzierungen.
-The Company expects to report initial data from Part C of the DisTinGuish study in mid-2024
investors.leaptx.com/news-releases/...rter-and-full-year-2023
40 Mio. $ Privatplatzierung
- to extend cash runway into Q2 2026
investors.leaptx.com/news-releases/...llion-private-placement
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
79 | LEAP THERAPEUTICS nach der KE 2019 | centsucher | Vassago | 12.04.24 13:54 |